Si-DNMT1 restore tumor suppressor genes expression through the reversal of DNA hypermethylation in cholangiocarcinoma

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 2, 2014, Pages 181-189

  Xiang, Jifeng ^a   Luo, Fang ^a   Chen, Yong ^a   Zhu, Fangyu ^a   Wang, Jiming ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CADHERIN; CADHERIN 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA METHYLTRANSFERASE 1; PLASMID VECTOR; PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1; SI DNMT1; UNCLASSIFIED DRUG; DMAP1 PROTEIN, HUMAN; RASSF1 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; DENSITOMETRY; DNA METHYLATION; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MTT ASSAY; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; BILE DUCT TUMOR; GENETICS; METABOLISM; TUMOR CELL LINE;

BILE DUCT NEOPLASMS; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; GENE KNOCKOUT TECHNIQUES; HUMANS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84899487410     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.11.004     Document Type: Article

References (34)

1. Akoad M., Jenkins R. Proximal biliary malignancy. Surg Clin North Am 2008, 88:1409-1428.
2. Jarnagin W.R., Fong Y., DeMatteo R.P., Gonen M., Burke E.C., Bodniewicz B.S.J., et al. Staging, resectability, and outcome in 225patients with hilar cholangiocarcinoma. Ann Surg 2001, 234:507-517.
3. Chen Y., Gao W., Luo J., Tian R., Sun H., Zou S. Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. Oncol Rep 2011, 25:443-451.
4. Dong S.W., Cui Y.T., Zhong R.R., Liang D.C., Liu Y.M., Wang Y.G., et al. Decreased expression of retinoblastoma protein-interacting zinc-finger gene 1 in human esophageal squamous cell cancer by DNA methylation. Clin Lab 2012, 58:41-51.
5. Fendri A., Khabir A., Hadri-Guiga B., Sellami-Boudawara T., Daoud J., Frikha M., et al. Epigenetic alteration of the Wnt inhibitory factor-1 promoter is common and occurs in advanced stage of Tunisian nasopharyngeal carcinoma. Cancer Invest 2010, 28:896-903.
6. Ng E.K., Leung C.P., Shin V.Y., Wong C.L., Ma E.S., Jin H.C., et al. Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. PLoS One 2011, 6:e22233.
7. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998, 72:141-196.
8. Ling Y., Huang G., Fan L., Wei L., Zhu J., Liu Y., et al. CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma. J Clin Pathol 2011, 64:246-251.
9. Chinnasri P., Pairojkul C., Jearanaikoon P., Sripa B., Bhudhisawasdi V., Tantimavanich S., et al. Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke-related cholangiocarcinoma. Hum Pathol 2009, 40:817-826.
10. Tannapfel A., Sommerer F., Benicke M., Weinans L., Katalinic A., Geissler F., et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol 2002, 197:624-631.
11. Abouzeid H.E., Kassem A.M., Abdel Wahab A.H., El-mezayen H.A., Sharad H., Abdel Rahman S. Promoter hypermethylation of RASSF1, MGMT, and HIC-1 genes in benign and malignant colorectal tumors. Tumour Biol 2011, 32:845-852.
12. Wang T., Liu H., Chen Y., Liu W., Yu J., Wu G. Methylation associated inactivation of RASSF1 and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. J Exp Clin Cancer Res 2009, 28:160.
13. Wang Y., Yu Z., Wang T., Zhang J., Hong L., Chen L. Identification of epigenetic aberrant promoter methylation of RASSF1 in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 2007, 56:289-294.
14. Wong N., Li L., Tsang K., Lai P.B., To K.F., Johnson P.J. Frequent loss of chromosome 3p and hypermethylation of RASSF1 in cholangiocarcinoma. J Hepatol 2002, 37:633-639.
15. Kim B.H., Cho N.Y., Choi M., Lee S., Jang J.J., Kang G.H. Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas. Arch Pathol Lab Med 2007, 131:923-930.
16. Yang B., House M.G., Guo M., Herman J.G., Clark D.P. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 2005, 18:412-420.
17. Arai E., Kanai Y., Ushijima S., Fujimoto H., Mukai K., Hirohashi S. Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 2006, 119:288-296.
18. Sarkar S., Abujamra A.L., Loew J.E., Forman L.W., Perrine S.P., Faller D.V. Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res 2011, 31:2723-2732.
19. Xu M., Gao J., Du Y.Q., Gao D.J., Zhang Y.Q., Li Z.S., et al. Reduction of pancreatic cancer cell viability and induction of apoptosis mediated by siRNA targeting DNMT1 through suppression of total DNA methyltransferase activity. Mol Med Report 2010, 3:699-704.
20. Tao Q., Huang H., Geiman T.M., Lim C.Y., Fu L., Qiu G.H., et al. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002, 11:2091-2102.
21. Nasimuzzaman M., Waris G., Mikolon D., Stupack D.G., Siddiqui A. Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor. J Virol 2007, 81:10249-10257.
22. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8:286-298.
23. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159.
24. Sandhu D.S., Shire A.M., Roberts L.R. Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets. Liver Int 2008, 28:12-27.
25. Bheemanaik S., Reddy Y.V., Rao D.N. Structure, function and mechanism of exocyclic DNA methyltransferases. Biochem J 2006, 399:177-190.
26. Brown R., Plumb J.A. Demethylation of DNA by decitabine in cancer chemotherapy. Expert Rev Anticancer Ther 2004, 4:501-510.
27. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Köhler G., Wijermans P., et al. Demethylation of a hypermethylated CDKN2B/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002, 100:2957-2964.
28. Fang J.Y., Yang L., Zhu H.Y., Chen Y.X., Lu J., Lu R., et al. 5-Aza-2'-deoxycitydine induces demethylation and up-regulates transcription of CDKN2AINK4A gene in human gastric cancer cell lines. Chin Med J (Engl) 2004, 117:99-103.
29. Fan H., Zhao Z., Quan Y., Xu J., Zhang J., Xie W. DNA methyltransferase 1 knockdown induces silenced CDH1 gene reexpression by demethylation of methylated CpG in hepatocellular carcinoma cell line SMMC-7721. Eur J Gastroenterol Hepatol 2007, 19:952-961.
30. Jung Y., Park J., Kim T.Y., Park J.H., Jong H.S., Im S.A., et al. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. J Mol Med (Berl) 2007, 85:1137-1148.
31. Bennett M.R., Hasty J. A DNA methylation-based switch generates bistable gene expression. Nat Genet 2007, 39:146-147.
32. Bowen N.J., Palmer M.B., Wade P.A. Chromosomal regulation by MeCP2: structural and enzymatic considerations. Cell Mol Life Sci 2004, 61:2163-2167.
33. Ying J., Poon F.F., Yu J., Geng H., Wong A.H., Qiu G.H., et al. DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer 2009, 100:663-669.
34. Shen W.J., Dai D.Q., Teng Y., Liu H.B. Regulation of demethylation and re-expression of RASSF1 gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB. World J Gastroenterol 2008, 14:595-600.